Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common StockGlobeNewsWire • 02/04/21
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/21
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate ProgressGlobeNewsWire • 11/12/20
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted CancersGlobeNewsWire • 10/24/20
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid TumorsGlobeNewsWire • 10/12/20
Revolution Medicines (RVMD) Looks Good: Stock Adds 6.9% in SessionZacks Investment Research • 09/22/20
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) InhibitorsGlobeNewsWire • 09/16/20
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment ConferenceGlobeNewsWire • 09/09/20
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development ConferenceGlobeNewsWire • 09/08/20
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate ProgressGlobeNewsWire • 08/10/20
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common StockGlobeNewsWire • 07/09/20
Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel CoronavirusGlobeNewsWire • 06/30/20
Revolution Medicines Provides Research and Development Update for its Portfolio of Novel Targeted Cancer TherapiesGlobeNewsWire • 06/22/20
Revolution Medicines Announces Dosing of First Patient in Clinical Study of RMC-4630 (SAR442720) Combined with PD-1 InhibitorGlobeNewsWire • 06/22/20
Revolution Medicines Announces Dosing of First Patient in Phase 1b Combination Study of RMC-4630 and AMG 510GlobeNewsWire • 06/09/20
Revolution Medicines Announces Four Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting IIGlobeNewsWire • 05/19/20
Revolution Medicines Reports First Quarter 2020 Financial Results and Continued Corporate ProgressGlobeNewsWire • 05/14/20
Revolution Medicines Announces Publication of Scientific Paper Describing Anti-Tumor Immunity Induced by SHP2 Inhibitor in Preclinical Cancer ModelsGlobeNewsWire • 04/29/20
Revolution Medicines Announces Issuance of U.S. Patent Covering Compositions of Matter for its Clinical-Stage SHP2 Inhibitor ProgramGlobeNewsWire • 03/18/20
New Clinical Trial Exploring Revolution Medicines’ Investigational SHP2 Inhibitor RMC-4630 in Combination with an ERK Inhibitor Announced by Netherlands Cancer InstituteGlobeNewsWire • 03/09/20